Compare Microchip Technology Inc. (MCHP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Microchip Technology Inc. trades at $82.68 (market cap $43.72B), while State Street SPDR S&P Biotech ETF trades at $153.77. The key difference: Microchip Technology Inc. pays a 2.26% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Microchip Technology Inc. nearer its low. Which is the better fit depends on your goals.
| MCHP | XBI | |
|---|---|---|
Market Cap | $43.72B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $102.97 | $164.28 |
52-Week Low | $49.02 | $85.16 |
Enterprise Value | $49.01B | — |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $80.64, down 0.4% on the day, with technical indicators signaling a bearish trend. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $0.70 EPS. Revenue declined to $4.40B in 2025, resulting in a net loss, but margins are projected to recover in 2026. Positive sentiment is driven by AI and aerospace demand, with 68% of analysts rating it a Buy.
Outlook is mixed: strong analyst consensus targets $113.33, but high P/E of 368 and recent net loss pose valuation risks. Key opportunities include AI data center growth and inventory recovery, while supply chain constraints and semiconductor cycle volatility remain headwinds. The stock offers upside if earnings rebound as forecasted.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
